Bakkt Holdings (BKKT) reported third-quarter earnings of $0.89 per share on revenue of $148.2 million on Earnings Whispers' normalized basis. Earnings fell 25.8% year over year, and revenue fell 63.2%. No consensus estimate or Earnings Whisper was available, so there is no surprise to measure. The company's own release shows GAAP diluted EPS of $0.31 and revenue of $149.2 million, down 62.9%. That gap reflects differences in normalization, not a discrepancy in the underlying business. The quarter is a study in contrast. Bakkt reiterated an aggressive $3 billion full-year 2026 volume target and added a $6 billion target for the first half of 2027. Yet reported transacting volume went backward, cash kept draining, and the profit line again rested on a mark-to-market gain.

The quality of the earnings deserves scrutiny. Net income attributable to Bakkt was $14.3 million, a swing from a $14.9 million loss a year ago. That included a $26.8 million non-cash gain on the Transchem warrants. Strip that out and the company was still losing money at the operating level, with a $14.4 million operating loss. The underlying improvement is real but modest. Operating expenses excluding crypto costs and execution fees fell 40% to $16.1 million. The operating loss narrowed 42.9%, and the adjusted EBITDA loss improved by $3.0 million to $11.8 million. Investors should also note that Bakkt redefined adjusted EBITDA this quarter to exclude other income. Under the old definition, Q3 2025 had shown a $28.7 million profit, propped up by a derivative gain. The recast is arguably more honest, but it changes the comparison baseline. Sequentially, GAAP net income dropped from $80.8 million in Q2, and both quarters were driven by Transchem gains.

The operating trends beneath the targets are weaker than the targets themselves. Third-quarter Total Transacting Volume fell to $147.9 million from $168.8 million in Q2 on lower trading activity, bringing nine-month TTV to $557.9 million. Reaching $3 billion therefore requires roughly $2.4 billion in Q4 alone, about 16 times the Q3 pace. Management's case is that institutional and cross-border clients were integrating during the quarter, activations began in October, and volume should rise significantly from November. A newly built commercial team is converting the existing pipeline, and live clients' settlement and treasury flows are expected to recur. That is a credible mechanism on paper. Notably, the full-year target was lifted to $3 billion from $2.5 billion in September, before the weak Q3 print was known publicly. Doubling down despite it signals either real visibility into activations or a willingness to stretch.

Other forward markers lean the same way. September monthly active users, reported for the first time, were 9,760 against an unchanged December target of about 25,000, which requires roughly 2.5x growth in a single quarter. On the positive side:

• The Bakkt Payments Portal is live for business clients.
• Network reach expanded to 75+ countries from 63.
• Strategic Asset Value rose to $145.2 million from $118.6 million.
• A stablecoin credit card-as-a-service program with Thredd was announced.
• A cross-border institutional trading desk is targeted for a Q4 launch.

Several earlier commitments, however, quietly softened. The Q2 expectation of adjusted EBITDA breakeven in Q4 2026 was not repeated. Bakkt Agent launches that previously carried a Q4 date are now undated and subject to readiness and approvals. Management offered no stabilized gross margin or take-rate assumption, which matters because TTV is explicitly not revenue or profit. A previously touted Zoth partnership went unmentioned.

Balance-sheet runway is the risk bears will press hardest. Cash and restricted cash fell to $37.3 million from $50.7 million in Q2 and $82.6 million in Q1. Q3 operating cash burn was $17.9 million. Bakkt carries no long-term debt and sold no shares under its at-the-market program during the quarter. Even so, at the current burn rate the cushion is roughly two quarters. Much of the reported asset value sits in Transchem warrants that carry transfer and monetization constraints. The tone of the call also shifted. A new CFO, Matt White, replaced Karen Alexander in August, the commentary was more heavily caveated, and no analyst questions were taken, leaving the ramp narrative untested.

Market context is thin. No current price or sentiment reading was available. For reference, shares opened at $7.24 after the August report, below the current 200-day moving average of $8.56. The more relevant near-term signal will be fundamental, not technical. Starting in December, the monthly Bakkt Engine Report will publish completed-month TTV and annualized run-rate volume. That gives investors an unusually quick, public check on whether the November inflection is materializing.

The bottom line is that Bakkt has turned its story into a single, falsifiable bet: a dramatic Q4 volume ramp funded by a shrinking cash balance. Cost discipline is genuine. But the reported profit is a warrant mark, volume declined sequentially, and the breakeven and product-timing commitments softened. The December and January monthly volume reports will matter far more than this quarter's headline EPS.